Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on November 5, 2024, the appointment of Vinay Shah as the new Chief Financial Officer effective November 16, 2024. Shah, with over 25 years of experience in the pharmaceutical and healthcare sectors, previously served as CFO at Virpax Pharmaceuticals and Aravive, Inc. His financial expertise is expected to support Adial's strategic goals, including advancing their lead investigational drug, AD04. Concurrently, Joseph Truluck, the outgoing CFO, has entered into a Separation Agreement with Adial, effective November 1, 2024. Truluck will continue as a consultant to ensure a smooth transition until March 31, 2025. His departure is not due to any disagreements with the company's practices or policies. Adial's lead product, AD04, is aimed at treating Alcohol Use Disorder and potentially other addictive disorders, showing promising results in recent clinical trials.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on November 5, 2024, the appointment of Vinay Shah as the new Chief Financial Officer effective November 16, 2024. Shah, with over 25 years of experience in the pharmaceutical and healthcare sectors, previously served as CFO at Virpax Pharmaceuticals and Aravive, Inc. His financial expertise is expected to support Adial's strategic goals, including advancing their lead investigational drug, AD04. Concurrently, Joseph Truluck, the outgoing CFO, has entered into a Separation Agreement with Adial, effective November 1, 2024. Truluck will continue as a consultant to ensure a smooth transition until March 31, 2025. His departure is not due to any disagreements with the company's practices or policies. Adial's lead product, AD04, is aimed at treating Alcohol Use Disorder and potentially other addictive disorders, showing promising results in recent clinical trials.